Archer Materials (ASX:AXE) integrated its graphene field effect transistor sensors with electrical readout circuitry in a new chip as it seeks to integrate the Biochip into an at-home testing device for
chronic kidney disease, according to a Thursday ASX filing.
The chips were fabricated at foundry partner VTT Technical Research Centre of Finland via a multi-project wafer run on a 200mm wafer. Chips from the wafer are being packaged for testing at the firm.
It will continue the integration work in parallel with the ongoing development of the Biochip. The Biochip development and integration activities will be targeted at having early prototypes of the system and demonstration of initial potassium testing accuracy performance early in 2026.
The Biochip needs to be integrated with cartridge fluidics for the delivery of the blood sample for sensing. Integrating the Biochip with miniaturized electronics is a key step in this regard.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.